Introduction: Chimeric antigen receptor T cell (CAR-T) therapy has shown success in treating hematological malignancies, but its effectiveness against solid tumors is hindered by T cell exhaustion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback